AMAG Pharmaceuticals upgraded to Hold from Underperform at Jefferies Jefferies upgraded AMAG Pharmaceuticals to Hold citing limited downside potential after the FDA issued a complete response letter for Feraheme broader use. The firm raised its price target for shares to $19 from $16.
On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: AMAG Pharmaceuticals (AMAG) initiated with an Outperform at Northland... Angie's List (ANGI) initiated with a Neutral at Roth Capital... Bio Blast Pharma (ORPN) initiated with a Buy at Rodman & Renshaw... British American Tobacco (BTI) initiated with a Buy at UBS... Imperial Tobacco (ITYBY) initiated with a Buy at UBS... Instructure (INST) initiated with an Outperform at Barrington... Nektar (NKTR) initiated with a Buy at Janney Capital... Par Pacific (PARR) initiated with an Outperform at Imperial Capital... Pure Storage (PSTG) initiated with a Buy at Maxim... comScore (SCOR) initiated with a Hold at Evercore ISI.